

Dolby Laboratories, Inc.  
Form 8-K  
August 14, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**August 12, 2014**

**DOLBY LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-32431**  
**(Commission**  
  
**File Number)**

**90-0199783**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Dolby Laboratories, Inc. - Form 8-K

**100 Potrero Avenue**

**San Francisco, CA 94103-4813**

**(Address of principal executive offices) (Zip Code)**

**(415) 558-0200**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 8 Other Events**

**Item 8.01 Other Events.**

On August 12, 2014, Dolby Laboratories, Inc. (the Company ) was informed by the U.S. Federal Trade Commission that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has been terminated in connection with the Company s proposed acquisition of Doremi Technologies LLC, a Delaware limited liability company. The transaction remains subject to regulatory clearance from the European Commission and customary closing conditions.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DOLBY LABORATORIES, INC.**

By: /s/ ANDY SHERMAN  
Andy Sherman

Executive Vice President, General  
Counsel and Secretary

Date: August 14, 2014